1627696-51-8 Usage
Uses
Used in Pharmaceutical Industry:
LY-3177833 is used as an anticancer agent for its ability to inhibit Cdc7 kinase, a key enzyme in DNA replication initiation. By targeting this enzyme, LY-3177833 can potentially disrupt the rapid cell division and uncontrolled growth associated with cancer cells. Its effectiveness has been demonstrated in reducing tumor growth in an SW620 human colorectal adenocarcinoma mouse xenograft model when administered at various doses.
Used in Cancer Research:
In the field of cancer research, LY-3177833 serves as a valuable tool for studying the role of Cdc7 kinase in the regulation of DNA replication and its potential as a therapeutic target for various types of cancer. Its potent inhibitory activity and oral bioavailability make it a promising candidate for further investigation and development as a targeted cancer therapy.
Used in Drug Development:
LY-3177833 is used as a lead compound in the development of novel anticancer drugs. Its high specificity for Cdc7 kinase and its ability to inhibit phosphorylation of MCM2-S53 make it a valuable starting point for the design and synthesis of new compounds with improved potency, selectivity, and pharmacokinetic properties. This could ultimately lead to the development of more effective cancer treatments with fewer side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1627696-51-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,2,7,6,9 and 6 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1627696-51:
(9*1)+(8*6)+(7*2)+(6*7)+(5*6)+(4*9)+(3*6)+(2*5)+(1*1)=208
208 % 10 = 8
So 1627696-51-8 is a valid CAS Registry Number.
1627696-51-8Relevant articles and documents
CDC7 Inhibitors
-
, (2014/09/29)
The present invention provides isoindolinone compounds, or a pharmaceutically acceptable salt thereof, that inhibit CDC7 and, therefore may be useful in treating cancer.